Nintedanib Moves Closer to Mesothelioma Standard of Care

Treatment & Doctors
Reading Time: 3 mins
Publication Date: 01/24/2018
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite’s Article


Povtak, T. (2020, October 16). Nintedanib Moves Closer to Mesothelioma Standard of Care. Retrieved February 5, 2023, from


Povtak, Tim. "Nintedanib Moves Closer to Mesothelioma Standard of Care.", 16 Oct 2020,


Povtak, Tim. "Nintedanib Moves Closer to Mesothelioma Standard of Care." Last modified October 16, 2020.

laboratory test tubes

The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom granted early access designation to nintedanib for the treatment of pleural mesothelioma, a major step forward for patients diagnosed with the asbestos-related cancer.

Nintedanib, marketed under the brand names Ofev and Vargatef, is a small-molecule enzyme inhibitor. In clinical trials, the drug has shown the ability to prevent mesothelioma cell growth and slow tumor spread (metastasis).

“This is potentially quite significant,” Dr. Dean Fennell, chair of thoracic medical oncology at the University of Leicester and University Hospitals of Leicester NHS Trust, told “Certainly, this drug is promising. Fantastic news.”

The U.S. Food and Drug Administration (FDA) in December 2016 granted nintedanib an orphan drug designation for mesothelioma, encouraging its use before officially approving it.

MHRA and the FDA are moving the drug another step closer to changing the long-accepted but relatively ineffective standard-of-care treatment for unresectable pleural mesothelioma.

“This is an exciting prospect of what’s to come,” Fennell said. “The drug has shown real effectiveness.”

Nintedanib Effective in Other Cancers

Doctors in the U.K. and U.S. diagnose an estimated 2,500 to 3,000 combined cases of mesothelioma each year.

U.K. doctors have used nintedanib in combination with chemotherapy to treat certain lung cancers, but this recent designation as a “Promising Innovative Medicine” (PIM) expands its use significantly.

The FDA previously approved nintedanib for pulmonary fibrosis, but until a year ago it was only available to mesothelioma patients through clinical trials. The drug has worked well in relieving breathing problems by softening the lungs.

The latest U.K. designation stems from the phase II portion of an ongoing LUME-Meso clinical trial conducted at 134 sites worldwide. It is measuring the effectiveness of nintedanib in combination with chemotherapy against chemotherapy alone.

Clinical Trials Show Nintedanib’s Effectiveness

Early results of the trial include a progression-free survival of 9.4 months with the combination treatment, compared to just 4.7 months for chemotherapy alone. The overall survival benefit was 18.3 months against 14.2 months.

The clinical trial — which is still accepting new patients — has moved into phase III with an expected completion of Oct. 30, 2019. Only patients with the epithelioid subtype of mesothelioma are eligible.

There are five trial sites within the U.K. and 10 in the U.S., including:

The Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, in conjunction with the National Cancer Institute, is conducting a nintedanib clinical trial involving recurrent pleural mesothelioma, but without chemotherapy.

Researchers at Institut Gustave Roussy in France are conducting a trial for mesothelioma involving a combination of nintedanib and pembrolizumab (Keytruda).

Oncologists involved in earlier trials with nintedanib and mesothelioma were equally impressed with the drug.

“There is a lot of excitement about this drug right now,” Dr. Rama Balaraman at Florida Cancer Affiliates in Ocala, told “It is potentially a new way of approaching this disease.”

open book icon vector illustration
Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide